Acute nicotine alteration of sensory memory impairment in smokers with schizophrenia

Journal of Clinical Psychopharmacology

Volumn 30, Issue 5, 2010, Pages 541-548

  Dulude, Louise ^a   Labelle, Alain ^a,b   Knott, Verner J ^a,b  

^a UNIVERSITY OF OTTAWA   (Canada)

^b ROYAL OTTAWA HOSPITAL   (Canada)

Author keywords

event related potentials; mismatch negativity; MMN; nicotine; schizophrenia; sensory memory; tobacco

Indexed keywords

ARIPIPRAZOLE; CLOZAPINE; FLUPHENAZINE; NICOTINE GUM; OLANZAPINE; PLACEBO; QUETIAPINE; RISPERIDONE; ZUCLOPENTHIXOL;

ADULT; ARTICLE; AUDITORY MEMORY; AUDITORY STIMULATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; EVENT RELATED POTENTIAL; HUMAN; MALE; MEMORY DISORDER; MISMATCH NEGATIVITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SENSORY MEMORY; SMOKING; SMOKING CESSATION;

ACOUSTIC STIMULATION; ADULT; AUDITORY PERCEPTION; DOUBLE-BLIND METHOD; HUMANS; MALE; MEMORY DISORDERS; NICOTINE; SCHIZOPHRENIA; SMOKING;

EID: 77957271407     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e3181f0c9c6     Document Type: Article

References (83)

1. Kumari V, Postma P. Nicotine use in schizophrenia: the self-medication hypotheses. Neurosci Biobehav Rev. 2005;29: 1021-1034. (Pubitemid 41097398)
2. Evans D, Drobes D. Nicotine self-medication of cognitive-attentional processing. Addict Biol. 2009;14: 32-42.
3. Gehricke J, Loughlin S, Whalen C, et al. Smoking to self-medicate attentional and emotional dysfunctions. Nicotine Tob Res. 2007; 9(suppl 4): S523-S536. (Pubitemid 350246199)
4. Sacco K, Bannon K, George T. Nicotinic receptor mechanisms and cognition in normal states and neuropsychiatric disorders. J Psychopharmacol. 2004;18: 457-474. (Pubitemid 39665114)
5. Javitt D. Sensory processing in schizophrenia: neither simple nor intact. Schizophr Bull. 2009;35: 1059-1064.
6. Javitt D. When doors of perception close: bottom-up models of disrupted cognition in schizophrenia. Annu Rev Clin Psychol. 2009;5: 249-275.
7. Wexler B, Stevens A, Bowers A, et al. Word and tone working memory deficits in schizophrenia. Arch Gen Psychiatry. 1998;55: 1093-1096. (Pubitemid 28558281)
8. Javitt D, Strous R, Grochowski S, et al. Impaired precision, but normal retention, of auditory sensory (Bechoic[) memory information in schizophrenia. J Abnorm Psychol. 1997;106: 315-324. (Pubitemid 27184752)
9. Strous R, Cowan N, Ritter W, et al. Auditory sensory (Bechoic[) memory dysfunction in schizophrenia. Am J Psychiatry. 1995;152: 1517-1519.
10. Lu Z, Williamson S, Kaufman L. Behavioural lifetime of human auditory sensory memory predicted by physiological measures. Science. 1992;258: 668-1670. (Pubitemid 23012443)
11. Näätänen R. The mismatch negativityVa powerful tool for cognitive neuroscience. Ear Hear. 1995;16: 6-18.
12. Näätänen R, Paavilainen P, Rinne T, et al. The mismatch negativity (MMN) in basic research of central auditory processing: a review. Clin Neurophysiol. 2007;118: 2544-2590. (Pubitemid 350182437)
13. Näätänen R, Winkler I. The concept of auditory stimulus representation in neuroscience. Psychol Bull. 1999;125: 826-859.
14. Schröger E. Mismatch negativity: a microphone into auditory memory. J Psychophysiol. 2007;21: 138-146. (Pubitemid 351516000)
15. Sussman E. A new view on the MMN and attention debate: the role of context in processing auditory events. J Psychophysiol. 2007;21: 164-175. (Pubitemid 351516002)
16. Kujala T, Tervaniemi M, Schröger E. The mismatch negativity in cognitive and clinical neuroscience: theoretical and methodological considerations. Biol Psychol. 2007;74: 1-19. (Pubitemid 44794431)
17. Umbricht D, Krljes S. Mismatch negativity in schizophrenia: a meta-analysis. Schizophr Res. 2005;75: 1-23. (Pubitemid 40824557)
18. Näätänen R, Kähkönen S. Central auditory dysfunction in schizophrenia as revealed by the mismatch negativity (MMN) and its magnetic equivalent MMNm: a review. Int J Neuropsychopharmacol. 2008;12: 125-135.
19. Kasai K, Yamada H, Kamio S, et al. Do high or low doses of anxiolytics and hypnotics affect mismatch negativity in schizophrenia subjects? An EEG and MEG study. Clin Neurophysiol. 2002;113: 141-150. (Pubitemid 34093867)
20. Umbricht D, Javitt D, Novak G, et al. Effects of clozapine and auditory event-related potentials in schizophrenia. Biol Psychiatry. 1998;44: 716-725. (Pubitemid 28496787)
21. Umbricht D, Javitt D, Novak G, et al. Effects of risperidone on auditory event-related potentials in schizophrenia. Int J Neuropsychopharmacol. 1999;2: 299-304.
22. Schall U, Catts S, Chaturvedi S, et al. The effect of clozapine therapy on frontal lobe dysfunction in schizophrenia: neuropsychology and event-related potential measures. Int J Neuropsychopharmacol. 1998;1: 19-29. (Pubitemid 128538361)
23. Engeland C, Mahoney C, Mohr E, et al. Acute nicotine effects on auditory sensory memory in tacrine treated and nontreated patients with Alzheimer's disease: an event-related potential study. Pharmacol Biochem Behav. 2002;72: 457-464.
24. Harkrider A, Hedrick M. Acute effects of nicotine on auditory gating in smokers and non-smokers. Hear Res. 2005;202: 114-128. (Pubitemid 40469775)
25. Martin L, Davalos D, Kisley M. Nicotine enhances automatic temporal processing as measured by the mismatch negativity waveform. Nicotine Tob Res. 2009;11: 698-706.
26. Baldeweg T, Wong D, Stephan K. Nicotinic modulation of human auditory sensory memory: evidence from mismatch negativity potentials. Int J Psychophysiol. 2006;59: 49-58. (Pubitemid 43081886)
27. Inami R, Kirino E, Inove R, et al. Transdermal nicotine administration enhances automatic auditory processing reflected by mismatch negativity. Pharmacol Biochem Behav. 2005;80: 453-461. (Pubitemid 40299347)
28. Dunbar G, Boeijinga PH, Demazières A, et al. Effects of TC-1734 (AZD3480), a selective neuronal nicotinic receptor agonist, on cognitive performance and the EEG of young healthy male volunteers. Psychopharmacol. 2007;191: 919-929. (Pubitemid 46399143)
29. Inami R, Kirino E, Inove R, et al. Nicotine effects on mismatch negativity in schizophrenia patients. Neuropsychobiol. 2007;56: 64-72. (Pubitemid 351340016)
30. Mitchie P. What has MMN revealed about the auditory system in schizophrenia. Int J Psychophysiol. 2001;42: 177-194.
31. Mitchie P, Budd T, Todd J, et al. Duration and frequency mismatch negativity in schizophrenia. Clin Neurophysiol. 2000;111: 1054-1065. (Pubitemid 30316345)
32. Molholm S, Martinez A, Ritter W, et al. The neural circuitry of pre-attentive auditory change-detection: an fMRI study of pitch and duration mismatch negativity generators. Cereb Cortex. 2005;15: 545-551. (Pubitemid 40577471)
33. Frodl-Bauch T, Kathmann N, Moller H, et al. Dipole localization and test-retest reliability of frequency and duration mismatch negativity generator processes. Brain Topogr. 1997;10: 3-8. (Pubitemid 27489973)
34. Giard M, Lavaikainen J, Reinekainen K, et al. Separate representation of stimulus frequency, intensity, and duration, in auditory sensory memory: an event-related potential and dipole-model analysis. J Cogn Neurosci. 1995;7: 133-143.
35. Ochoa E, Lasaide-Dominicci J. Cognitive deficits in schizophrenia: focus and neuronal nicotinic acetylcholine receptors and smoking. Cell Mol Neurobiol. 2007;27: 609-639. (Pubitemid 47038107)
36. Kay S, Fiszbein A, Opler L. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13: 261-271. (Pubitemid 18039085)
37. Blair J, Spreen O. Predicting premorbid IQ: a revision of the North American Reading Test. Clin Neuropsychol. 1989;3: 129-136.
38. Heatherton T, Kozlowski L, Freckor R, et al. The Fagerstrom Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance Questionnaire. Br J Addict. 1991;86: 1119-1127.
39. Hukkanen J, Jacob P III, Benowitz N. Metabolism and disposition kinetics of nicotine. Pharmacol Rev. 2005;57: 79-115. (Pubitemid 40283970)
40. Hughes J, Hatsukami D. Signs and symptoms of tobacco withdrawal. Arch Gen Psychiatry. 1986;43: 289-294. (Pubitemid 16052281)
41. Woestenburg J, Verbaten M, Slengen J. The removal of the eye-movement artifact from the EEG by progression analysis in the frequency domain. Biol Psychol. 1983;16: 127-147. (Pubitemid 13121223)
42. Paavilainen P, Alho K, Reinkainen K, et al. Right hemisphere dominance of different mismatch negativities. Electroencephalogr Clin Neurophysiol. 1991: 78: 466-479.
43. Bolton S, Bon C. Pharmaceutical Statistics: Practical and Clinical Applications. New York, NY: Dekker; 2004.
44. Shelley A-M, Ward P, Catts S, et al. Mismatch negativity: an index of a preattentive processing deficit in schizophrenia. Biol Psychiatry. 1991;30: 1059-1062.
45. Catts S, Shelley A-M, Ward P, et al. Brain potential evidence for an auditory sensory memory deficit in schizophrenia. Am J Psychiatr. 1995;152: 213-219.
46. Davalos D, Kisley M, Ross R. Effects of interval duration on temporal processing in schizophrenia. Brain Cognition. 2003;52: 295-301. (Pubitemid 36945412)
47. Davalos D, Kisley M, Polk S, et al. Mismatch negativity in detection of interval duration deviation in schizophrenia. NeuroReport. 2003; 14: 1283-1286. (Pubitemid 36928604)
48. Davalos D, Kisley M, Freedman R. Behavioural and electrophysiological indices of temporal processing dysfunction in schizophrenia. J Neuropsychiatry Clin Neurosci. 2005;17: 517-525. (Pubitemid 41790053)
49. Umbricht D, Koller E, Schmid L, et al. How specific are deficits in mismatch negativity generation to schizophrenia? Biol Psychiatry. 2003;53: 1120-1131. (Pubitemid 36695087)
50. Wan L, Crawford H, Boutros N. Early and late auditory sensory gating: moderating influences from schizotypal personality, tobacco smoking status of acute smoking. Psychiatry Res. 2007;151: 11-20. (Pubitemid 46634627)
51. Guney F, Genc B, Kutlo R, et al. Auditory P300 event-related potential in tobacco smokers. J Clin Neurosci. 2009;16: 1311-1315.
52. Thaker G. Neurophysiological endophenotypes across bipolar and schizophrenia psychosis. Schizophr Bull. 2008;34: 760-773. (Pubitemid 351957568)
53. Church R, Meck W, Gibbon J. Application of scalar timing to individual trials. J Exp Psychol Anim Behav Process. 1994;20: 135-155.
54. Gibbon J, Church R, Meck W. Scalar timing in memory. Ann N Y Acad Sci. 1984;423: 52-77. (Pubitemid 14122529)
55. Meck W. Neuropharmacology of timing and time perception. Cogn Brain Res. 1996;3: 227-242. (Pubitemid 26198355)
56. Dani J, De Biazi M. Cellular mechanisms of nicotine addiction. Pharmacol Biochem Behav. 2001;70: 439-446. (Pubitemid 34131638)
57. Meck W, Church R. Cholinergic modulation of the content of temporal memory. Behav Neurosci. 1987;101: 457-464. (Pubitemid 18014839)
58. Meck W, Williams C. Characterization of the facilitative effects of perinatal choline supplementation on timing and temporal memory. NeuroReport. 1997;8: 2831-2835. (Pubitemid 27394801)
59. Cheng R-K, Meck W, Williams C. >7 Nicotinic acetylcholine receptors and temporal memory: synergistic effects of combining prenatal choline and nicotine on reinforcement-induced resetting of an interval clock. Learn Mem. 2006;13: 127-134.
60. Leonard S, Adams C, Breese C, et al. Nicotinic receptor function in schizophrenia. Schizophr Bull. 1996;22: 431-445. (Pubitemid 26295346)
61. Martin L, Freedman R. Schizophrenia and the alpha 7 nicotinic acetylcholine receptor. Int Rev Neurobiol. 2007;78: 225-246.
62. Javitt D. Intracortical mechanisms of mismatch negativity dysfunction in schizophrenia. Audiol Neurootol. 2000;5: 207-218. (Pubitemid 30312189)
63. Javitt D, Steinscheider M, Schroeder C, et al. Role of cortical N-methyl-D-aspartate in auditory sensory memory and mismatch negativity generation: implications for schizophrenia. Proc Natl Acad Sci USA. 1996;23: 11962-11967. (Pubitemid 26347231)
64. Korostenskaja M, Nikulin V, Kicic D, et al. Effects of a NMDA receptor antagonist memantine on mismatch negativity. Brain Res Bull. 2007;72: 275-283. (Pubitemid 46602746)
65. Kreitschmann-Andermahr L, Rosburg T, Demme V, et al. Effect of ketamine on the neuromagnetic mismatch field in healthy humans. Cogn Brain Res. 2001;12: 109-116. (Pubitemid 32728286)
66. Tikhonravov D, Neuvonen T, Pertovaara A, et al. Effects of an NMDA receptor antagonist MK-801 on an MMN-like response recorded in anesthetized rats. Brain Res. 2008;1203: 97-102.
67. Umbricht D, Schmid L, Koller R, et al. Ketamine-induced deficits in auditory and visual context-dependent processing in healthy volunteers: implications for models of cognitive deficits in schizophrenia. Arch Gen Psychiatry. 2000;57: 1139-1147.
68. Leonard S, Adams C, Breese C, et al. Nicotinic receptor function in schizophrenia. Schizophr Bull. 1996;22: 431-445. (Pubitemid 26295346)
69. Martin L, Freedman R. Schizophrenia and the alpha 7 nicotinic acetylcholine receptor. Int Rev Neurobiol. 2007; 78: 225-246.
70. Mobascher A, Winterer G. The molecular and cellular neurobiology of nicotine abuse in schizophrenia. Pharmacopsychiatry. 2008; 41(suppl 1): S51-S59.
71. Ochoa E, Lasaide-Dominicci J. Cognitive deficits in schizophrenia: focus on neuronal nicotinic acetylcholine receptors and smoking. Cell Mol Neurobiol. 2007;27: 609-639. (Pubitemid 47038107)
72. Vidal C. Nicotinic potentiation of glutamatergic synapses in the prefrontal cortex: new insights into the analysis of the role of nicotinic receptors in cognitive functions. Drug Develop Res. 1994;31: 120-126. (Pubitemid 24090776)
73. McGee D, Heath M, Gelber S, et al. Nicotine enhancement of fast excitatory synaptic transmission in CNS by presynaptic receptors. Science. 1995;269: 1692-1696.
74. Aramakis V, Metherate R. Nicotine selectivity enhances NMDA receptor-mediated synaptic transmission during potential development in sensory neorortex. J Neurosci. 1998;18: 8485-8495. (Pubitemid 28465023)
75. Yamuzaki Y, Jea Y, Niu R, et al. Nicotine exposure in vivo induces long-lasting enhancement of NMDA receptor-mediated currents in the hippocampus. Eur J Neurosci. 2006;23: 1819-1828.
76. Morgan C, Curran H. Acute and chronic effects of ketamine upon human memory: a review. Psychopharmacology. 2006;188: 408-424. (Pubitemid 46758974)
77. Levin E, McClernan F, Rezvani A. Nicotinic effects on cognitive function: behavioural characterization, pharmacological specification, and anatomic localization. Psychopharmacology. 2006;184: 523-539. (Pubitemid 43255869)
78. Knott V, McIntosh J, Millar A, et al. Nicotine and smoker status moderate brain electric and mood activation induced by ketamine, an N-methyl-D-aspartate (NMDA) receptor antagonist. Pharmacol Biochem Behav. 2006;85: 228-242. (Pubitemid 44772925)
79. Leiser S, Bowlby M, Comery T, et al. A cog in cognition: how the >7 nicotinic acetylcholine receptor is geared towards improving cognitive deficits. Pharmacol Ther. 2009;122: 302-311.
80. Baldeweg T, Klugman A, Gruzelier J, et al. Impairment in frontal but not temporal components of mismatch negativity in schizophrenia. Int J Psychophysiol. 2002;43: 111-122. (Pubitemid 34059258)
81. Olincy A, Stevens K. Treating schizophrenia symptoms with an alpha 7 nicotinic agonist, from mice to men. Biochem Pharmacol. 2007;74: 1192-1201. (Pubitemid 47417932)
82. Martin L, Kim W, Freedman R. Alpha-7 nicotinic receptor agonists: potential new candidates for the treatment of schizophrenia. Psychopharmacology. 2004;174: 54-64. (Pubitemid 38925091)
83. Olincy A, Harris J, Johnson L, et al. Proof-of-concept trial of an alpha 7 nicotinic agonist in schizophrenia. Arch Gen Psychiatry. 2006;63: 630-638. (Pubitemid 43848294)